OncoImmunology
Volume 11, 2022 - Issue 1
Open access
5,159
Views
9
CrossRef citations to date
0
Altmetric
Original Research
CXCL10-armed oncolytic adenovirus promotes tumor-infiltrating T-cell chemotaxis to enhance anti-PD-1 therapy
Xiaofei Lia Department of Oncology and Cancer Rehabilitation Centre, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, ChinaView further author information
, Mingjie Lua Department of Oncology and Cancer Rehabilitation Centre, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, ChinaView further author information
, Manman Yuanb State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, Jiangsu, ChinaView further author information
, Jing Yeb State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, Jiangsu, ChinaView further author information
, Wei Zhanga Department of Oncology and Cancer Rehabilitation Centre, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, ChinaView further author information
, Lingyan Xua Department of Oncology and Cancer Rehabilitation Centre, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, ChinaView further author information
, Xiaohan Wua Department of Oncology and Cancer Rehabilitation Centre, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, ChinaView further author information
, Bingqing Huia Department of Oncology and Cancer Rehabilitation Centre, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, ChinaView further author information
, Yuchen Yanga Department of Oncology and Cancer Rehabilitation Centre, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, ChinaView further author information
, Bin Weic Department of Oncology, The Affiliated Huaian No. 1 People’s Hospital of Nanjing Medical University, Huai’an, Jiangsu, ChinaView further author information
, Ciliang Guod Jiangsu Key Laboratory of Molecular Medicine, Medical School of Nanjing University, Nanjing, Jiangsu, ChinaView further author information
, Min Weid Jiangsu Key Laboratory of Molecular Medicine, Medical School of Nanjing University, Nanjing, Jiangsu, ChinaView further author information
, Jie Dongd Jiangsu Key Laboratory of Molecular Medicine, Medical School of Nanjing University, Nanjing, Jiangsu, ChinaCorrespondence[email protected]
View further author information
, View further author information
Xingxin Wub State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, Jiangsu, ChinaCorrespondence[email protected]
View further author information
& View further author information
Yanhong Gua Department of Oncology and Cancer Rehabilitation Centre, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, ChinaCorrespondence[email protected]
View further author information
show allView further author information
Article: 2118210
|
Received 21 Nov 2021, Accepted 24 Aug 2022, Published online: 31 Aug 2022
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.